Skip to content
Menu

AVITA Medical, Inc. RCEL

Full chart Compare
Set alert

Price alert · RCEL

All alert types
15.62 USD -0.37 (-2.31%)

Regular-session close

15.62 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

15.51 Day range 16.26
3.22 52-week range 18.43
YTD
+352.75%
1 year
+306.77%

5D +0.30 (+1.91%)

151617FriMonTueWedThu15.99
Market cap
494.96M
Revenue (ttm)
60.04M
Profit margin
-95.47%
EPS (ttm)
-1.17
Shares out
26.22M
Forward P/E
-14.33
YTD return
+352.75%
1-year return
+306.77%
50-day average
11.87
Volume
386.99K
Avg volume
415.69K
Open
15.76
Previous close
15.99
Day's range
15.51 – 16.26
52-week range
3.22 – 18.43
Beta
1.54
Analysts
Buy
Price target
16.81 (+7.6%)

Key statistics

200-day average
10.61
Enterprise value
309.80M
Price / sales
5.13
Price / book
25.21
Revenue growth
43.20%
Free cash flow
-33.68M
Total cash
44.41M
Total debt
45.63M
Return on equity
-152.44%
Short % of float
4.49%

Fundamental scorecard

5 of 25 checks passed on RCEL’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
RCEL Revenue — quarterly 26.11M
RCEL Net income — quarterly -6.22M
RCEL EPS — quarterly -0.20

Earnings

RCEL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.42-0.62-0.20-47.62%
Aug 8, 2024Jun 1, 2024-0.59-0.60-0.01-1.69%
May 13, 2024Mar 1, 2024-0.26-0.73-0.47-180.77%
Feb 22, 2024Dec 1, 2023-0.34-0.28+0.06+17.65%
Nov 9, 2023Sep 1, 2023-0.53-0.34+0.19+35.85%
Aug 10, 2023Jun 1, 2023-0.34-0.41-0.07-20.59%

Upgrades / downgrades

RCEL analyst upgrades and downgrades
DateFirmActionFromTo
Nov 8, 2024Piper SandlerreitNeutralNeutral
Aug 9, 2024Cantor FitzgeraldreitOverweightOverweight
May 14, 2024Piper SandlerdownOverweightNeutral
May 14, 2024Cantor FitzgeraldmainOverweightOverweight
Apr 11, 2024BTIGdownBuyNeutral
Feb 23, 2024Piper SandlerreitOverweightOverweight

About AVITA Medical, Inc.

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on RCEL — it syncs with the Stock Master app.

Institution ownership

RCEL institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.10%1,860,51921.86MSep 29, 2024
Vanguard Group Inc5.41%1,417,67216.66MSep 29, 2024
Geode Capital Management, LLC2.27%594,4366.98MSep 29, 2024
State Street Corporation1.98%519,9976.11MSep 29, 2024
Essex Investment Management Co LLC0.88%231,0942.72MSep 29, 2024
Northern Trust Corporation0.83%216,4672.54MSep 29, 2024

Fund ownership

RCEL fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund3.05%800,7199.41MSep 29, 2024
iShares Russell 2000 ETF2.50%656,6847.72MOct 30, 2024
Vanguard Extended Market Index Fund1.48%389,2034.57MSep 29, 2024
Fidelity Small Cap Index Fund1.00%262,4203.08MAug 30, 2024
iShares Russell 2000 Growth ETF0.88%231,6472.72MOct 30, 2024
Fidelity Extended Market Index Fund0.55%145,1501.71MOct 30, 2024